To overcome the historical issue of oncolytic viruses being sequestered by the liver, Accession re-engineers a human virus so it cannot infect any human cells. Only after this safety step is it re-targeted to infect only cancer cells, ensuring precise delivery and avoiding systemic side effects.

By simultaneously targeting dozens of functionally unrelated survival genes across different chromosomes, Nuago's therapy makes it statistically improbable for cancer cells to mutate and develop escape routes. This multi-pronged attack from a single drug construct is a core advantage over therapies that cancer can evolve around.

To overcome on-target, off-tumor toxicity, LabGenius designs antibodies that act like biological computers. These molecules "sample" the density of target receptors on a cell's surface and are engineered to activate and kill only when a specific threshold is met, distinguishing high-expression cancer cells from low-expression healthy cells.

To reduce risk, Nuago prioritizes cancers based on two criteria: high unmet medical need and the existence of clinically validated delivery methods for that specific tissue. This strategy separates their novel drug science from novel delivery science, allowing them to focus resources on proving their mechanism without inventing a delivery system.

Cytospire targets well-validated antigens like EGFR, which were previously 'undruggable' by CD3 engagers due to severe toxicity on healthy cells. Their gamma delta T-cell platform solves this by enabling 'context-dependent killing,' discriminating between tumor and healthy tissue. This safety profile could unlock a portfolio of solid tumor targets previously considered too dangerous for this drug class.

The therapy’s targets are fundamental survival genes conserved from worms to humans. This deep biological foundation makes the treatment 'cancer-agnostic,' effective regardless of tumor origin, subtype, or the patient's genetic background. The company has successfully killed 66 different tumor types across seven species.

Unlike therapies targeting a single cell death pathway like apoptosis, Nuago's DICE (Death Induced by Survival Gene Elimination) triggers a systemic collapse. By silencing numerous survival genes, it disrupts core cellular networks, activating all 22 known molecular cell death pathways at once, making it impossible for the cancer cell to escape.

Unlike conventional treatments, Nuago's therapy is more effective against highly aggressive, late-stage tumors. The very biological traits that define aggressiveness—loss of microRNAs and upregulation of survival genes—are the exact vulnerabilities Nuago's platform exploits, making the most dangerous cancers the most responsive to treatment.

Nuago leverages the 'seed-mediated off-target effect'—a bug for single-gene therapies—as a feature. Their short RNAs use a six-nucleotide seed to promiscuously target hundreds of survival and oncogenes, achieving a broad therapeutic effect where 'off-target' is the entire point, making unintended effects impossible.